Coenzyme Q - cytochrome c reductase

Coenzyme Q - cytochrome c reductase

UCR_TM
Identifiers
Symbol UCR_TM
Pfam InterPro IPR004192
SCOP SUPERFAMILY TCDB OPM superfamily OPM protein 3cx5
ubiquinol—cytochrome-c reductase
Identifiers
EC number CAS number IntEnz BRENDA ExPASy KEGG MetaCyc metabolic pathway
PRIAM PDB structures PDBsum
Gene Ontology EGO


The coenzyme Q : cytochrome c — oxidoreductase, sometimes called the cytochrome bc1 complex, and at other times complex III, is the third complex in the proteins.

Ubiquinol—cytochrome-c reductase catalyzes the chemical reaction

QH2 + 2 ferricytochrome c \rightleftharpoons Q + 2 ferrocytochrome c + 2 H+

Thus, the two substrates of this enzyme are dihydroquinone (QH2) and ferri- (Fe3+) cytochrome c, whereas its 3 products are quinone (Q), ferro- (Fe2+) cytochrome c, and H+.

This enzyme belongs to the family of oxidoreductases, specifically those acting on diphenols and related substances as donor with a cytochrome as acceptor. This enzyme participates in oxidative phosphorylation. It has four cofactors: cytochrome C1, cytochrome b-562, cytochrome b-566 and a 2-Iron ferredoxin.

Nomenclature

The systematic name of this enzyme class is ubiquinol:ferricytochrome-c oxidoreductase. Other names in common use include:

  • coenzyme Q-cytochrome c reductase,
  • dihydrocoenzyme Q-cytochrome c reductase,
  • reduced ubiquinone-cytochrome c reductase, complex III,
  • (mitochondrial electron transport),
  • ubiquinone-cytochrome c reductase,
  • ubiquinol-cytochrome c oxidoreductase,
  • reduced coenzyme Q-cytochrome c reductase,
  • ubiquinone-cytochrome c oxidoreductase,
  • reduced ubiquinone-cytochrome c oxidoreductase,
  • mitochondrial electron transport complex III,
  • ubiquinol-cytochrome c-2 oxidoreductase,
  • ubiquinone-cytochrome b-c1 oxidoreductase,
  • ubiquinol-cytochrome c2 reductase,
  • ubiquinol-cytochrome c1 oxidoreductase,
  • CoQH2-cytochrome c oxidoreductase,
  • ubihydroquinol:cytochrome c oxidoreductase,
  • coenzyme QH2-cytochrome c reductase, and
  • QH2:cytochrome c oxidoreductase.

Human Gene Names

MTCYB: mtDNA encoded cytochrome b; mutations associated with exercise intolerance

CYC1:cytochrome c1

CYCS: cytochrome c

UQCRFS1: Rieske Iron sulfur protein

UQCRB: Ubiquinone binding protein, mutation linked with mitochondrial complex III deficiency nuclear type 3

UQCRH: hinge protein

UQCRC2: Core 2, mutations linked to mitochondrial complex III deficiency, nuclear type 5

UQCRC1: Core 1

UQCR: 6.4KD subunit

UQCR10: 7.2KD subunit

TTC19: Newly identified subunit, mutations linked to complex III deficiency nuclear type 2

Structure

Compared to the other major proton-pumping subunits of the electron transport chain, the number of subunits found can be small, as small as three polypeptide chains. This number does increase, and eleven subunits are found in higher animals.[2] Three subunits have prosthetic groups. The cytochrome b subunit has two b-type hemes (bL and bH), the cytochrome c subunit has one c-type heme (c1), and the Rieske Iron Sulfur Protein subunit (ISP) has a two iron, two sulfur iron-sulfur cluster (2Fe•2S).

Structures of complex III: 1L0L

Reaction

It catalyzes the reduction of cytochrome c by oxidation of coenzyme Q (CoQ) and the concomitant pumping of 4 protons from the mitochondrial matrix to the intermembrane space:

QH2 + 2 cytochrome c (FeIII) + 2 H+in → Q + 2 cytochrome c (FeII) + 4 H+out

In the process called Q cycle,[3][4] two protons are consumed from the matrix (M), four protons are released into the inter membrane space (IM) and two electrons are passed to cytochrome c.

Reaction Mechanism

The reaction mechanism for complex III (Cytochrome bc1, Coenzyme Q: Cytochrome C Oxidoreductase) is known as the ubiquinone ("Q") cycle. In this cycle four protons get released into the Positive "P" side (inter membrane space), but only two protons get taken up from the Negative "N" side (matrix). As a result a proton gradient is formed across the membrane. In the overall reaction, two ubiquinols are oxidized to ubiquinones and one ubiquinone is reduced to ubiquinol. In the complete mechanism, two electrons are transferred from ubiquinol to ubiquinone, via two cytochrome c intermediates.

Overall:

  • 2 x QH2 oxidised to Q
  • 1 x Q reduced to QH2
  • 2 x Cyt c1 reduced
  • 4 x H+ released into intermembrane space
  • 2 x H+ picked up from matrix

The reaction proceeds according to the following steps:

Round 1:

  1. Cytochrome b binds a ubiquinol and a ubiquinone.
  2. The 2Fe/2S center and BL heme each pull an electron off the bound ubiquinol, releasing two hydrogens into the intermembrane space.
  3. One electron is transferred to cytochrome c1 from the 2Fe/2S centre, whilst another is transferred from the BL heme to the BH Heme.
  4. Cytochrome c1 transfers its electron to cytochrome c (not to be confused with cytochrome c1), and the BH Heme transfers its electron to a nearby ubiquinone, resulting in the formation of a ubisemiquinone.
  5. Cytochrome c diffuses. The first ubiquinol (now oxidised to ubiquinone) is released, whilst the semiquinone remains bound.

Round 2:

  1. A second ubiquinol is bound by cytochrome b.
  2. The 2Fe/2S center and BL heme each pull an electron off the bound ubiquinol, releasing two hydrogens into the intermembrane space.
  3. One electron is transferred to cytochrome c1 from the 2Fe/2S centre, whilst another is transferred from the BL heme to the BH Heme.
  4. Cytocrome c1 then transfers its electron to cytochrome c, whilst the nearby semiquinone picks up a second electron from the BH Heme, along with two protons from the matrix.
  5. The second ubiquinol (now oxidised to ubiquinone), along with the newly formed ubiquinol are released.[5]

Inhibitors of complex III

There are three distinct groups of Complex III inhibitors.

  • Antimycin A binds to the Qi site and inhibits the transfer of electrons in Complex III from heme bH to oxidized Q (Qi site inhibitor).
  • Myxothiazol and stigmatellin binds to the Qo site and inhibits the transfer of electrons from reduced QH2 to the Rieske Iron sulfur protein. Myxothiazol and stigmatellin bind to distinct pockets within the Qo site.
    • Myxothiazol binds very close to cytochrome bL (hence termed a "proximal" inhibitor).
    • Stigmatellin binds near the Rieske Iron sulfur protein, with which it strongly interacts.

Some have been commercialized as fungicides (the strobilurin derivatives, best known of which is azoxystrobin; QoI inhibitors) and as anti-malaria agents (atovaquone).

Also propylhexedrine inhibits cytochrome c reductase.[6]

Oxygen free radicals

A small fraction of electrons leave the electron transport chain before reaching complex IV. Premature electron leakage to oxygen results in the formation of superoxide. The relevance of this otherwise minor side reaction is that superoxide and other reactive oxygen species are highly toxic and are thought to play a role in several pathologies, as well as aging (the free radical theory of aging).[7] Electron leakage occurs mainly at the Qo site and is stimulated by antimycin A. Antimycin A locks the b hemes in the reduced state by preventing their re-oxidation at the Qi site, which, in turn, causes the steady-state concentrations of the Qo semiquinone to rise, the latter species reacting with oxygen to form superoxide. The effect of high membrane potential is thought to have a similar effect.[8] Superoxide produced at the Qo site can be released both into the mitochondrial matrix[9][10] and into the intermembrane space (from where it can reach the cytosol.[9][11] This could be explained by the fact that Complex III might produce superoxide as membrane permeable HOO rather than as membrane impermeable O2-..[10]

Mutations in Complex III genes in human disease

Mutations in Complex III-related genes typically manifest as exercise intolerance.[12][13] Other mutations have been reported to cause septo-optic dysplasia[14] and multisystem disorders.[15] However, mutations in BCS1L, a gene responsible for proper maturation of Complex III, can result in Björnstad syndrome and the GRACILE syndrome, which in neonates are lethal conditions that have multisystem and neurologic manifestations typifying severe mitochondrial disorders. The pathogenicity of several mutations has been verified in model systems such as yeast.[16]

The extent to which these various pathologies are due to bioenergetic deficits or overproduction of superoxide is presently unknown.

See also

Additional images

References

Further reading

External links

  • complex site (Edward A. Berry) at lbl.gov
  • complex site (Antony R. Crofts) at uiuc.edu
  • complex at scripps.edu
  • MDL Chime)
  • families/superfamily-3 - Calculated positions of bc1 and related complexes in membranes
  • Medical Subject Headings (MeSH)